BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
Phase Ib / II study to determine the Maximum Tolerated Dose and Recommended Phase II Dose, and to evaluate the safety and antitumour activity, of BI 836845 and everolimus in combination with exemestane in women with HR+/HER2- advanced breast cancer
Epistemonikos ID: 27041cca056e86ce7786c229856f92faa2f0ee28
First added on: May 11, 2024